Edwards Lifesciences Corporation $EW Stock Purchased by Aberdeen Group plc

Edwards Lifesciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group increased its Edwards Lifesciences stake by 49.9% in the third quarter, adding 248,305 shares to hold 745,667 shares worth about $64.4 million. Institutional investors collectively own 79.46% of the company.
  • Edwards Lifesciences reported quarterly EPS of $0.80, beating estimates of $0.74, while revenue of $1.72 billion exceeded expectations and rose 10.5% year over year.
  • Analysts maintain a “Moderate Buy” consensus, with an average price target of $109.56; several firms recently raised their targets.
  • Five stocks to consider instead of Edwards Lifesciences.

Aberdeen Group plc increased its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 49.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 745,667 shares of the medical research company's stock after acquiring an additional 248,305 shares during the period. Aberdeen Group plc owned about 0.13% of Edwards Lifesciences worth $64,366,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Edwards Lifesciences during the second quarter worth about $5,318,092,000. Varma Mutual Pension Insurance Co bought a new stake in Edwards Lifesciences in the second quarter worth about $11,168,000. Assenagon Asset Management S.A. boosted its stake in Edwards Lifesciences by 50.0% in the third quarter. Assenagon Asset Management S.A. now owns 2,719,271 shares of the medical research company's stock valued at $234,727,000 after acquiring an additional 906,345 shares during the last quarter. Conway Capital Management Inc. purchased a new position in Edwards Lifesciences in the second quarter valued at about $954,000. Finally, Commerce Bank purchased a new position in Edwards Lifesciences in the second quarter valued at about $3,121,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 48,900 shares of the firm's stock in a transaction on Monday, November 9th. The shares were sold at an average price of $103.05, for a total transaction of $5,039,145.00. Following the sale, the vice president owned 22,798 shares in the company, valued at approximately $2,349,333.90. This trade represents a 68.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of the firm's stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 53,945 shares of company stock worth $5,498,306 in the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Price Performance

NYSE EW traded up $1.36 during trading hours on Friday, hitting $107.16. The company had a trading volume of 3,822,134 shares, compared to its average volume of 4,833,862. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.86 and a current ratio of 4.60. The firm has a market capitalization of $61.62 billion, a price-to-earnings ratio of 60.54, a PEG ratio of 2.82 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $74.66 and a 52 week high of $107.69. The firm has a 50 day simple moving average of $90.42 and a 200 day simple moving average of $86.32.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.06. The company had revenue of $1.72 billion for the quarter, compared to the consensus estimate of $1.68 billion. Edwards Lifesciences had a return on equity of 16.06% and a net margin of 15.30%. The firm's revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 earnings per share. Equities research analysts expect that Edwards Lifesciences Corporation will post 3.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. BTIG Research raised their price target on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Sanford C. Bernstein lifted their price target on shares of Edwards Lifesciences from $99.00 to $106.00 and gave the stock a "market perform" rating in a report on Thursday, November 5th. Royal Bank Of Canada upped their price objective on Edwards Lifesciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. TD Cowen upped their price objective on Edwards Lifesciences from $117.00 to $121.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Mizuho set a $120.00 price objective on Edwards Lifesciences in a report on Thursday, November 5th. Twenty-three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $109.56.

Get Our Latest Analysis on Edwards Lifesciences

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

See Also

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Edwards Lifesciences Right Now?

Before you consider Edwards Lifesciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.

While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines